NCT03905265View on ClinicalTrials.gov

Dose-finding Study of Moxidectin for Treatment of Scabies

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 13, 2020

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions
Scabies
Interventions
DRUG

Moxidectin Oral Product

The required number of moxidectin 2 mg oral tablets will be administered as a single dose with placebo to match as required

Trial Locations (5)

Unknown

Royal Darwin Hospital, Darwin

Medizinischen Universität Wien, Vienna

Hopital Henri Mondor AP-HP, Créteil

CHU Nice Hopital Archet 2, Nice

CHU Saint-Etienne Hopital Nord, Saint-Priest-en-Jarez

All Listed Sponsors
lead

Medicines Development for Global Health

OTHER

NCT03905265 - Dose-finding Study of Moxidectin for Treatment of Scabies | Biotech Hunter | Biotech Hunter